EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study

Hiroko Hasegawa iD, Rin Inamoto, Keiji Sugiyama, Naoki Izawa, Seiichiro Mitani, Takeshi Kawakami, Satoshi Yuki, Hidekazu Hirano, Saori Mishima, Tetsutaro Hamano, Toshiki Masuishi

Therapeutic Advances in Medical Oncology · 2026-08 · 18

DOI: 10.1177/17588359261476046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 06.08.2026. Verfasst von Hiroko Hasegawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, NHO Osaka National Hospital, Osaka, Japan. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiho Pharmaceutical Co., Ltd. Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) have been reported to exhibit resistance to various cytotoxic agents, including fluorouracil. A preclinical study showed that trifluridine, a key active component of FTD/TPI, retained antitumor activity in 5-FU-refractory dMMR CRC cell lines. However, the efficacy of trifluridine/tipiracil (FTD/TPI), with or without bevacizumab, in patients with MSI-H/dMMR mCRC remains poorly understood.

Objectives

This study aimed to evaluate the clinical efficacy and safety of FTD/TPI, with or without bevacizumab, specifically in patients with MSI-H/dMMR mCRC.

Design

A retrospective, multicenter observational study was conducted across 10 hospitals in Japan.

Methods

We identified patients with MSI-H/dMMR mCRC treated with FTD/TPI as second- or later-line therapy between June 2012 and January 2023. All eligible patients were divided into two groups: FTD/TPI monotherapy (FT group) and FTD/TPI combined with bevacizumab (FTB group); the safety and efficacy of the two groups were compared. Whole-exome sequencing (WES) was performed on available samples to explore genomic features associated with treatment response of FTD/TPI.

Results

The objective response rate (ORR) was 16.7% (95% confidence interval [CI], 3.6–41.4); median progression-free survival (PFS) was 5.5 months, and median overall survival (OS) was 11.8 months in the overall cohort. Although the median PFS was similar between the two groups (5.6 months in the FTB group and 5.2 months in the FT group, p =0.34), the ORR (22.2% vs. 11.1%, p =0.53), disease control rate (DCR; 88.9% vs. 55.6%, p =0.77) and median OS (18.9 months in the FTB group and 7.1 months in the FT group, p =0.18) were numerically better in the FTB group. WES revealed diverse genomic alterations, including those affecting DNA double-strand break repair-related genes, but no clear genomic biomarkers predictive of treatment response were identified.

Conclusions

FTD/TPI, with or without bevacizumab, demonstrated favorable antitumor activity in patients with MSI-H/dMMR mCRC. These findings suggest that FTD/TPI-based treatment may represent a potentially useful treatment option for this rare population, although further studies are warranted.

Schlagwörter

Stichwörter der Autor:innen

DNA mismatch repairFTD/TPImetastatic colorectal cancermicrosatellite instabilitywith or without bevacizumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, NHO Osaka National Hospital, Osaka, Japan.
  • Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
  • Department of Medical Oncology, NHO Nagoya Medical Center, Nagoya, Japan.
  • Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Japan.

ORCID-Profile: Hiroko Hasegawa

Förderung

  • Taiho Pharmaceutical Co., Ltd. Japan

Zitieren

APA

Hasegawa, H., Inamoto, R., Sugiyama, K., Izawa, N., Mitani, S., Kawakami, T., Yuki, S., Hirano, H., Mishima, S., Hamano, T., & Masuishi, T. (2026). Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261476046

Vancouver

Hasegawa H, Inamoto R, Sugiyama K, Izawa N, Mitani S, Kawakami T, et al. Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261476046

BibTeX
@article{Hasegawa2026,
  author = {Hasegawa, Hiroko and Inamoto, Rin and Sugiyama, Keiji and Izawa, Naoki and Mitani, Seiichiro and Kawakami, Takeshi and Yuki, Satoshi and Hirano, Hidekazu and Mishima, Saori and Hamano, Tetsutaro and Masuishi, Toshiki},
  title = {Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261476046}
}
Kostenlos starten →